蛋白激酶C:在糖尿病中治疗内皮功能障碍的潜在治疗点
Qian Xiao1, Dan Wang1, Danyang Li2
1Department of Laboratory, Ninth Forty Hospital of the Chinese People's Liberation Army Joint Security Force, Lanzhou 730050, Gansu, China; School of Public Health, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, Gansu, China.
Journal of diabetes and its complications
|August 4, 2023
概括
高葡萄糖激活蛋白激酶C (PKC) 有助于糖尿病内皮功能障碍. 抑制PKC可能为糖尿病患者提供新的治疗策略.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 内分泌学 在内分泌学.
背景情况:
- 蛋白激酶C (PKC) 是一个关键的信号分子,参与各种细胞过程.
- 内皮功能障碍是糖尿病的主要并发症.
- 糖尿病患者的高葡萄糖水平会激活PKC,导致细胞损伤.
研究的目的:
- 审查PKC在与糖尿病相关的内皮功能障碍中的作用.
- 总结目前针对PKC激活的治疗策略.
- 探索潜在的治疗方法来缓解糖尿病患者内皮功能障碍.
主要方法:
- 对PKC,糖尿病和内皮功能研究的文献综述.
- 分析高葡萄糖,DAG和PKC激活之间的机制.
- 关于PKC的药理抑制剂的概述.
主要成果:
- 在高葡萄糖下,PKC激活由二甲基甘油 (DAG) 介导,促进氧化应激和炎症.
- 这种PKC驱动的途径显著损害了内皮细胞的功能.
- 已经确定了几种针对PKC激活的药物.
结论:
- 在糖尿病内皮功能障碍的发病过程中,PKC起着至关重要的作用.
- 抑制PKC代表了管理糖尿病并发症的有希望的治疗途径.
- 对PKC抑制剂的进一步研究可能会为糖尿病患者带来新的治疗方法.
相关概念视频
cAMP-dependent Protein Kinase Pathways
6.4K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
204
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
204
Protein Kinases and Phosphatases
13.2K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
13.2K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K


